Prosecution Insights
Last updated: November 04, 2026
Application No. 19/099,784

A MONITORING DEVICE

Non-Final OA §102
Filed
Jan 30, 2025
Priority
Aug 01, 2022 — GB 2211188.4 +1 more
Examiner
WEHRHEIM, LINDSEY GAIL
Art Unit
3799
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Ceryx Medical Limited
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
1y 7m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
459 granted / 581 resolved
+9.0% vs TC avg
Strong +19% interview lift
Without
With
+19.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
22 currently pending
Career history
615
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
48.4%
+8.4% vs TC avg
§102
24.6%
-15.4% vs TC avg
§112
18.7%
-21.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 581 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 3, 4, 11, 13-18, 20, and 21 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Burton (WO 2005067790 A1, copy attached to Office action). Regarding claim 1, Burton discloses a cardiorespiratory monitoring device, configured to: receive sensor data comprising cardiac data and respiratory data for a subject (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); determine a respiratory sinus arrhythmia, RSA, value based on the cardiac data and the respiratory data (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); determine a cardio-respiratory phase synchronization, CRPS, value based on the cardiac data and the respiratory data (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15); and output a health indication for the subject based on the RSA value and the CRPS value (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15). Regarding claim 3, Burton discloses the device is configured to: receive activity data (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); determine a plurality of RSA values and a plurality of CRPS values during a period of physiological demand as indicated by the activity data; and determine the health indication based on the plurality of RSA values (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22) and the plurality of CRPS values (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15). Regarding claim 4, Burton discloses the device is configured to determine the health indication based on: a variation in the RSA values during the period of physiological demand (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); and a variation in the CRPS values during the period of physiological demand (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15). Regarding claim 11, Burton discloses the sensor data comprises a plurality of sensor readings over a time window and wherein the device is configured to determine a plurality of RSA values (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22) and a plurality of CRPS values (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15) and output the health indication based on the plurality of RSA values and the plurality of CRPS values (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15). Regarding claim 13, Burton discloses the device is configured to output the health indication to one or more of: a subject user interface; a clinician device; a pacemaker device; a peripheral stimulation device; an emergency responder device; and a remote monitoring centre (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 40, ln 27-34; page 42, ln 5-15; page 44, ln 12-15). Regarding claim 14, Burton discloses the device is configured to output therapeutic instructions to a subject user interface if the health indication is representative of cardiorespiratory stress in the subject (page 14, ln 33-page 15, ln 5; page 24, ln 26-29; page 44, ln 12-15). Regarding claim 15, Burton discloses the therapeutic instructions comprise one or more of: breathing instructions; activity instructions; and an instruction to seek immediate medical attention (page 14, ln 33-page 15, ln 5; page 24, ln 26-29; page 44, ln 12-15). Regarding claim 16, Burton discloses a cardiorespiratory monitoring system comprising: the device of claim 1 (see rejection above) and one or more sensors configured to provide the sensor data (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22). Regarding claim 17, Burton discloses a patient user interface for displaying the health indication (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 40, ln 27-34; page 42, ln 5-15; page 44, ln 12-15). Regarding claim 18, Burton discloses a method for providing a health indication, the method comprising: receiving sensor data comprising cardiac data and respiratory data for a subject (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); determining a respiratory sinus arrhythmia, RSA, value based on the cardiac data and the respiratory data (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); determining a cardio-respiratory phase synchronization, CRPS, value based on the cardiac data and the respiratory data (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15); and outputting a health indication for the subject patient based on the RSA value and the CRPS value (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15). Regarding claim 20, Burton discloses a cardiorespiratory monitoring device, configured to: receive sensor data comprising cardiac data and respiratory data for a subject (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); determine cardiorespiratory synchronization data based on the cardiac data and the respiratory data (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); determine a cardiorespiratory coupling factor based on a response of the cardiorespiratory synchronization data to a period of physiological demand as indicated by the sensor data (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15); and output a health indication for the subject based on the cardiorespiratory coupling factor (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15). Regarding claim 21, Burton discloses the device is configured to determine the cardiorespiratory synchronization data by determining one or more of: a plurality of respiratory sinus arrhythmia, RSA, values based on the cardiac data and the respiratory data (page 11, ln 26-page 12, ln 6; page 18, ln 30-34; page 21, ln 14-22); or a plurality of cardio-respiratory phase synchronization, CRPS. values based on the cardiac data and the respiratory data (page 18, ln 30-page 19, ln 7; page 19, ln 32-page 20, ln 12; page 42, ln 5-15). Allowable Subject Matter Claims 2, 5-10, and 12 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lindsey G Wehrheim whose telephone number is (571)270-5181. The examiner can normally be reached Monday - Friday 9 a.m. - 5 p.m. EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Niketa Patel can be reached at (571) 272-4156. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Lindsey G Wehrheim Primary Examiner Art Unit 3799 /LINDSEY G WEHRHEIM/Primary Examiner, Art Unit 3799
Read full office action

Prosecution Timeline

Jan 30, 2025
Application Filed
Sep 22, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779200
Percutaneous Circulatory Support Device with Expandable Element
3y 8m to grant Granted Nov 03, 2026
Patent 12779198
Percutaneous Circulatory Support Device with Cannula and Expandable Element
3y 8m to grant Granted Nov 03, 2026
Patent 12773549
CRIMP TOOL FOR COMPRESSIBLE CATHETER PUMP
4y 4m to grant Granted Oct 27, 2026
Patent 12766310
CIRCULATORY SUPPORT DEVICE WITH STEERABLE CANNULA
3y 7m to grant Granted Oct 20, 2026
Patent 12766307
BLOOD PUMP BLOOD COMPATIBILITY DEVICE
3y 7m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
98%
With Interview (+19.4%)
3y 4m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 581 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month